Drug intelligence / Profile preview

AZD-0292

Development stage: Phase 2
Lead developer: AstraZeneca
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AZD-0292 is a bispecific monoclonal antibody under development by AstraZeneca for the treatment of bronchiectasis. It is designed to target both the type III secretion protein PcrV and the polysaccharide synthesis locus (psl), which are associated with pathogenic mechanisms in respiratory diseases. The drug is administered intravenously and is currently in Phase 1 clinical trials for bronchiectasis[1][3][7].

Targets

Psl (Pseudomonas aeruginosa Psl exopolysaccharide)PcrV (Type III secretion protein PcrV)

Beyond the preview

Go deeper on AZD-0292.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD-0292.

Explore the full profile